April 14, 2007
Perineurioma: A Distinctive and Underrecognized Peripheral Nerve Sheath Neoplasm
By Macarenco, Ricardo S; Ellinger, Fred; Oliveira, Andre M
Context.-Perineuriomas are benign peripheral nerve sheath neoplasms composed of perineurial cells with characteristic immunohistochemical and ultrastructural features. They have been traditionally classified into two main types according to their location-intraneural and extraneural- and overlap histologically with many other tumors, which may be diagnostically challenging to general surgical pathologists.Objective.-To review the clinical, morphologic, immunohistochemical, ultrastructural, cytogenetic, and molecular genetic aspects of perineurioma, as well as to discuss its clinicopathologic variants and differential diagnosis.
Data Sources.-English-language literature published between 1966 and 2005 was reviewed.
Conclusions.-The correct identification of perineuriomas is important to avoid unnecessary overtreatment. The histologic diagnosis should be confirmed through immunohistochemical studies (including epithelial membrane antigen, S100 protein, and more recently described antibodies such as claudin-1 and GLUT1) or electron microscopy. Cytogenetic and molecular genetic studies are still of limited value for the diagnosis of perineuriomas but may play a fundamental role in excluding important differential diagnoses and also in helping elucidate the biology of these poorly known neoplasms.
(Arch Pathol Lab Med. 2007;131:625-636)
Described by Lazarus and Trombetta in 1978,1 perineurioma is an uncommon and underrecognized neoplasm defined as a peripheral nerve sheath tumor composed exclusively of neoplastic perineurial cells that demonstrate ultrastructural and immunohistochemical features similar to those of their normal cell counterpart.2,3 Normal perineurial cells constitute the perineurium, a protective barrier situated between the epineurium and endoneurium layers of the nerves that surround both myelinated and unmyelinated axon-Schwann cell complexes of peripheral nerve fascicles. The perineurium has direct continuity with the pia-arachnoid membrane of the central nervous system.4
In contrast to other peripheral nerve sheath tumors, perineuriomas have not been found to be associated to neurofibromatosis. They mainly affect adults, but some cases have been described in children.5-7 Two main forms of perineurioma exist: intraneural and extraneural. Intraneural perineuriomas are restricted to peripheral nerve boundaries, while extraneural perineuriomas are found mainly in soft tissues and skin. Extraneural perineuriomas seem to be more common than intraneural perineuriomas, and although they usually have no connection to peripheral nerves, sometimes such an association may be apparent in small lesions.6,8 In some cases, extraneural perineuriomas and intraneural perineuriomas may contain residual entrapped Schwann cells, axons, and fibroblasts.6,9 On the basis of different clinical and pathologic characteristics, extraneural perineuriomas are further subclassified into soft tissue,10 sclerosing,6 and reticular (retiform)11,12 subtypes. It is important for pathologists to be familiar with the histopathologic features of perineuriomas so as to avoid getting confused with a variety of malignant mesenchymal tumors and, thereby, avert overly aggressive intervention.
The objective of this article is to review the clinicopathologic subtypes of perineurioma, highlighting their morphologic and immunohistochemical aspects and their main differential diagnoses. Ultrastructural, cytogenetic, and molecular genetic findings of perineuriomas are also reviewed.
Extraneural Soft Tissue Perineurioma
Extraneural soft tissue perineurioma (ESTP) is a benign peripheral nerve sheath neoplasm that often occurs in the subcutaneous tissues of the trunk and limbs as a painless, solitary nodule or mass. Less frequently, it can be restricted to the dermis13 or occur in deep soft tissues. Some examples have also been described in the head and neck area, retroperitoneum,14 brain, kidney, and intestines.15-17 Despite the initial observations suggesting that females were more frequently affected,9 more recent series have shown that ESTP has no sex or age predilection; it has been observed in both young children and older individuals.5,14 Macroscopically, the tumors are usually white to gray, are well circumscribed but not encapsulated, and have a firm consistency (Figure 1, A). Most cases range in size from 1.5 to 7 cm,9 but very large and very small examples measuring 20 and 0.3 cm, respectively, are on record. 14 Histologically, ESTPs are composed of elongated neoplastic cells with wavy-shaped nuclei. However, their cytologic appearance varies; sometimes they are plumper and even epithelioid (Figure 1, B). Their cytoplasm shows slight eosinophilic features and indistinct cell boundaries (Figure 1, B). Characteristic spindle cells with tapering nuclei and elongated and extremely thin, widely separated bipolar cytoplasmic processes are found at least focally (Figure 1, C); these characteristic features can also be appreciated at the ultrastructural level (Figure 1, D). The cells may be disposed in varying manners, such as in a lamellar arrangement, perivascular whorling formation (Figure 2, A and B), or even short bundles with a vague storiform pattern reminiscent of that seen in dermatofibrosarcoma protuberans (Figure 2, C). The intercellular matrix may be abundant or scarce, which gives the lesion a hypocellular or hypercellular appearance, respectively (Figure 2, A and D). The stroma can vary from a more collagenous (Figure 3, A) to a more myxoid or loose appearance (Figure 2, A), and mixed collagenous-myxoid features can often be seen in the same lesion. Tissue cracking artifacts (Figure 3, B) and thick blood vessels (Figure 3, C) are also common. Mitotic figures and necrosis are usually absent, but in larger tumors central ischemic infarcts may be seen.14
The classic immunohistochemical profile of ESTP includes positivity for epithelial membrane antigen (EMA) (Figure 3, D), collagen type IV, laminin, and vimentin and negativity for S100 protein. The pattern of EMA expression reflects the elongated bipolar cytoplasmic processes of the tumor cells and varies: it may be strong and diffuse in some cases or just focal and weak in others, so that its detection is possible only at high-power examination in some instances. Hornick and Fletcher14 have shown that up to 65% of the cases are positive for CD34, but other series have shown negative results for this antigen.3,13 The causes for these discrepant data are probably related to different anti-CD34 antibodies, immunohistochemical protocols, or inclusion criteria used in these studies.3,13,14 Although several ESTPs are negative for pan-cytokeratins, 13,16 the expression of cytokeratins has not been widely studied in ESTP. Since their expression has already been detected in perineurial cells of pigs,18 in meningiomas,19 in sclerosing perineuriomas,6 and in reticular perineuriomas, 11 the expression of cytokeratins in at least a subset of ESTP would not be surprising.
Depending on location, ESTPs may mimic other lesions (Table). For those occurring in the superficial locations, the differential diagnosis mainly includes dermatofibrosarcoma protuberans (DFSP), soft tissue meningioma, and myxofibrosarcoma (Table). Dermatofibrosarcoma protuberans grows in a more diffuse storiform pattern, spreading along subcutaneous connective septa and adipose tissue with the characteristic honeycomb pattern. Most DFSPs are diffusely negative for EMA; however, DFSP may rarely express EMA, which can be a diagnostic challenge. 20 In such instances, molecular methods can help because DFSP is characterized by the presence of supernumerary ring chromosomes containing the t(17;22), which leads to the formation of the fusion gene COL1A1-PDGFB.21 The cytogenetic abnormality can be detected by using conventional cytogenetics on fresh tissues and fluorescent in situ hybridization or reverse transcriptase polymerase chain reaction on paraffin-embedded tissues. The cytogenetic and molecular genetic findings of perineuriomas are discussed later in this article.
The distinction between soft tissue meningioma and perineurioma is quite difficult and of little clinical value. Since perineurial cells and arachnoid cap cells (from which meningioma derives in the central nervous system) share significant morphologic and immunohistochemical similarities,22,23 both neoplasms have similar morphologic and immunohistochemical features. However, there may be some subtle differences at the ultrastructural level (eg, meningioma lacks pinocytotic vesicles). Moreover, because normal perineurial cells are continuous with the arachnoid membrane cap cells at the intervertebral foramina, some authors view perineurioma as the peripheral counterpart of meningioma.
For deep-seated perineuriomas, the differential diagnosis mainly includes desmoid-type fibromatosis, low-grade fibromyxoid sarcoma (LGFS), solitary fibrous tumor, low-grade leiomyosarcoma, leiomyoma, and myxofibrosarcoma (Table). We emphasize here the distinction of ESTP from desmoid-type fibromatosis, LGFS, and solitary fibrous tumor. The other elements of the differential diagnosis can be found in the Table. Fibromatosis is best distinguished by its long fascicles composed of spindle cells with tapering o\r plump vesicular nuclei, depicting a more homogeneous and dense collagenous matrix, and by diffuse expression of smooth muscle actin and musclespecific actin; these proteins are usually more focally detected in perineuriomas.14,24
Low-grade fibromyxoid sarcoma is a particularly difficult differential diagnosis since it may have overlapping histologic features with perineurioma. In contrast to this, LGFS exhibits alternation of more myxoid zones with more collagenous zones with arcade vessels, and occasionally giant collagen rosettes. Epithelial membrane antigen immunoexpression has been noticed in these tumors. 25 In difficult cases, one can rely on cytogenetics or molecular genetic analysis using reverse transcriptase polymerase chain reaction to detect, respectively, the translocation t(7;16)(q32?34;p11) or its fusion product FUS/CREB3L2 in LGFS.
In contrast to ESTP, solitary fibrous tumor is composed of bland ovoid-shaped to spindle-shaped cells without the cytologic features of perineurioma, arranged in the socalled patternless pattern, and has blood vessels often showing a hemangiopericytoma-like branching. Immunohistochemically, most solitary fibrous tumors are EMA negative and CD34 positive; however, a subset of cases may show focal EMA expression, which may cause difficulties in the differential diagnosis.26
Other differential diagnoses include benign peripheral nerve sheath tumors, such as schwannoma and neurofibroma. However, most cases can be easily differentiated at the morphologic level. In difficult cases, immunohistochemistry is helpful because S100 protein expression is rarely found in perineuriomas.9,14 Of note, similar to the concept of peripheral nerve sheath tumors with mixed schwannoma-neurofibroma features,27 benign peripheral nerve sheath tumors with hybrid features of perineurioma-neurofibroma and perineurioma-schwannoma have been recently recognized in small series by Zamecnik and Michal28 and by Michal et al,29 respectively. Other groups have encountered similar findings,30,31 and these neoplasms have been characterized morphologically, immunohistochemically, and in some examples ultrastructurally. 28- 30 They have a predilection for the skin and subcutaneous tissues of the trunk and upper extremities, and, in contrast to hybrid schwannoma-neurofibroma tumors,27 so far no cases have shown association with neurofibromatosis. Perhaps the most reasonable hypothesis for the divergent differentiation seen in peripheral nerve sheath neoplasms is their origin from a pluripotential precursor mesenchymal tissue or cell.27,32
Sclerosing perineurioma is an extraneural soft tissue perineurioma variant first described by Fetsch and Miettinen, 6 who reported 19 tumors, all arising in the hands, mainly of young male adults. Although ordinary ESTP outnumbers published cases of sclerosing perineurioma, the latter seems to be more common than the former in some institutions.33 However, a direct comparison between the frequencies of these two subtypes has not yet been established in the literature. Sclerosing perineurioma examples are well circumscribed and unencapsulated, have firm consistency, and are small (usually 3 cm or less in diameter). Microscopically these tumors may involve the dermis (Figure 4), dermis and subcutis simultaneously, or the subcutis alone.6 They are composed of small, plump, spindle-shaped or epithelioid cells with pale cytoplasm, indistinct cell borders, and nuclei presenting slight hyperchromatic features with granular chromatin and occasionally central small nucleoli (Figure 4, inset). These cells demonstrate corded, trabecular, or whorled growth patterns and are intermixed with prominent thick collagen bundles. Occasionally the cells are noted to cord or swirl around the blood vessels within the lesion, as well as around entrapped small nerve twigs (Figure 5, A through C). Capillaries and venules can be relatively numerous, and despite the presence of scattered mast cells and rare lymphocytes, these neoplasms do not feature a prominent inflammatory infiltrate. Tumor necrosis or prominent mitotic activity is not seen. The lesional cells demonstrate an immunoprofile similar to that of ESTP: they coexpress EMA, collagen type IV, and laminin and are negative for S100 protein. However, they usually lack CD34 expression and sometimes express cytokeratins, specifically CAM 5.2 and pan- cytokeratin cocktail.6 Muscle-specific actin and α-smooth muscle actin can be detected in a considerable percentage of cases.6
The differential diagnosis for sclerosing perineurioma mainly includes fibroma of tendon sheath, epithelioid glomus tumor, epithelioid sarcoma (Table), and highly collagenized examples of giant cell tumor of tendon sheath. Fibroma of tendon sheath is deeper seated than sclerosing perineurioma and is EMA negative.34 Glomus tumor differs from sclerosing perineurioma in that glomus cells have more abundant cytoplasm and diffusely express actins but not EMA. Giant cell tumor of tendon sheath frequently occurs in the fingers; some cases are extensively collagenized and may pose morphologic difficulties to the differential diagnosis with sclerosing perineurioma. However, giant cell tumor of tendon sheath is EMA negative as well.
Reticular (Retiform) Perineurioma
Reticular (retiform) perineurioma is a rare extraneural perineurioma variant with few examples reported in the literature. Although Michal12 first reported 4 cases in 1999 and named them retiform perineuriomas, Ushigome et al35 were the first to describe the reticular pattern in a perineurioma in 1986 (histologically well documented in Figure 4 of that manuscript). More recently, Graadt van Roggen et al11 described 6 more cases and preferred to name them reticular perineuriomas because, according to these authors, this term better indicates the netlike growing pattern of this neoplasm. The few cases described in these series occurred in adults, mostly women, with ages varying from 31 to 61 years. Most cases were subcutaneousbased lesions affecting the upper limbs (arms, hands, elbow, and fingers), although the occurrence in other anatomic sites, such as the gingiva, axilla, inguinal region, and deep soft tissues has also been documented.11,36,37 Interestingly, one intraneural example has been recently recorded. 38 Macroscopically, reticular perineurioma is usually a well-circumscribed firm mass whose color varies from yellowish to whitish to tan. Large lesions have been described, but the average size seems to be around 4 to 5 cm.11 Microscopically, most tumors are surrounded by a hypocellular pseudocapsule, but some examples have shown a poorly defined transition to the adjacent nonneoplastic tissues; a case has also been reported to infiltrate the adjacent muscle fibers.37 The neoplasm is composed of cells with centrally placed, oval to fusiform nuclei with inconspicuous nucleoli and palely eosinophilic cytoplasm embedded in a prominent myxoid stroma. Characteristically, the spindle cells demonstrate bipolar cytoplasmic processes that are frequently continuous with each other, forming a reticular or netlike growth pattern (Figure 6). Mitotic figures, necrosis, and hemorrhage are usually not identified, although focal slight nuclear atypia and nuclear hyperchromasia may be seen in some cases. The myxoid stroma demonstrates microcystic changes, and areas of stromal hyalinization may be seen. The vasculature is predominantly composed of small capillary-size blood vessels, but occasional large or ectatic vessels are also found within the lesion. Immunohistochemically, most reticular perineuriomas diffusely express EMA and are negative for S100 protein and smooth muscle actin; a subset of cases show focal expression of CD34, desmin, cytokeratin (AE1/AE3), and pan-cytokeratin (MNF116).11
The differential diagnosis mainly includes myoepithelial tumors, myxoid malignant peripheral nerve sheath tumor (MPNST), and myxoid synovial sarcoma (Table). Myoepithelial lesions may have histologic features similar to those of reticular perineurioma, but they often contain an acinar or ductal component and have a different immunophenotypic profile characterized by variable positivity for S100 protein, cytokeratins, glial fibrillary acidic protein, and smooth muscle actin.39
In contrast to reticular perineurioma, MPNST frequently demonstrates substantial nuclear atypia, significant mitotic figures, perivascular hypercellularity, and tumor necrosis. The reticular architecture is generally not seen in MPNST. Immunohistochemical studies are less useful in the distinction between these entities because MPNSTmay exhibit perineurial differentiation.40 About one half of the cases of MPNST demonstrate focal S100 protein positivity, and they are usually EMA negative.41
Synovial sarcoma with extensive myxoid changes can be differentiated from reticular perineurioma by fascicular spindle cell areas, greater nuclear atypia, and higher mitotic index. Within this morphologic context, EMA and cytokeratin positivity, as well as the frequent CD99 and Bcl-2 protein expression, point toward the correct diagnosis. In doubtful cases, molecular techniques may be of help, since cytogenetic procedures and reverse transcriptase polymerase chain reaction are able to detect, respectively, the translocation t(X;18)(p11.2;q11.2) and the corresponding most common chimeric fusion transcripts SYT-SSX1 and SYT-SSX242 in synovial sarcomas.
Intraneural perineurioma is a benign neoplasm composed exclusively of perineurial cells restricted to the boundaries of a nerve. This term was proposed by Emory et al2 to combine lesions previously classified as localized hypertrophic neuropathy, hypertrophic mononeuropathy, localized hypertrophic neurofibrosis, intraneural neurofibroma, and hypertrophic interstitial neuritis. Intraneural perineurioma primarily affects the extremities of young adu\lts and children, in whom it produces a fusiform expansion of a major nerve (Figure 7, A) with associated motor deficiency and occasional sensory loss. With exception of a case involving the spinal roots of both C8 and T1,2 the process is limited to a single nerve. It has rarely been described in unusual sites43 and in smaller, unnamed nerves.38,44 When occurring in such small nerves, no motor-sensorial disturbances may be clinically apparent. Histologic examination of a cross section of the affected nerve shows irregularly enlarged, hypercellular nerve fascicle (Figure 7, B) containing spindled perineurial cells arranged in pseudo-onion bulb-like whorls around one or more centrally situated Schwann cell and axons in varying stages of degeneration (Figures 7, C, and 8, A). Longitudinal sections may pose diagnostic difficulties because they do not depict the pseudo-onion bulb pattern characteristic of transverse sections. Instead, longitudinal sections show just ill- defined, parallel bundles of perineurial cells surrounding nearly indistinguishable nerve fibers (Figure 8, B). Immunohistochemistry reveals EMA-positive perineurial cells arranged in the pseudo-onion bulb whorls (Figure 8, C) around EMA-negative, S100-positive Schwann cells accompanying axonic structures.22 It should be differentiated from localized hypertrophic neuropathy (Table), an entity that, as defined by Scheithauer et al,9 is most likely a reactive condition that affects peripheral nerves, being characterized by nerve fascicle expansion due to the formation of onion bulb-like whorls of uniform S100-positive and EMA-negative Schwann cells (not perineurial cells as in intraneural perineurioma) encircling a variably myelinated axon.9,45
The nature of intraneural perineurioma had been a subject of debate,46-48 but the recent identification of clonal cytogenetic abnormalities in these lesions by Emory et al2 has confirmed its neoplastic nature.
ARE THE PERINEURIOMA VARIANTS INDEED DIFFERENT PRESENTATIONS OF THE SAME ENTITY?
According to some authors, perineurioma variants (ESTP, sclerosing perineurioma, reticular perineurioma, and intraneural perineurioma) can be viewed as part of a spectrum of different presentations of the same entity. Their similar ultrastructural features and the occurrence of rare cases with histopathologic features of more than one subtype13,38 support this impression. However, preliminary data suggest that there may be different genetic mechanisms for some of the perineurioma subtypes (see following section on cytogenetics and molecular genetics), 7,49 which consequently may have a different pathogenesis. Thus, at the present time, there is some uncertainty as to whether the 4 subtypes of perineurioma are indeed different presentations of the same entity.
Interestingly, other extremely rare histopathologic perineurioma variants have been reported, including perineurioma with granular cells,50 perineurioma with ossification, 51 perineurioma with adipocytes,52 plexiform perineurioma, 36 and the controversial cutaneous sclerosing Pacinian-like perineurioma.53
ELECTRON MICROSCOPY AND IMMUNOHISTOCHEMISTRY
In 1978, Lazarus and Trombetta1 described the first case of perineurioma in the soft tissues of the calf of a 45-yearold man, based on the ultrastructural similarity between the neoplastic cells to the normal perineurial cells, whose features include the presence of elongated, tapered nuclei with delicate chromatin; long thin cytoplasmic processes with pinocytotic vesicles; cell envelopment by basal lamina; and the presence of intercellular junctions, including tight junctions (Figure 1, D). Since then, electron microscopy has been considered the gold standard technique in confirming the diagnosis of perineurioma and its different variants.
With the advent of immunohistochemistry, Pinkus and Kurtin,54 in 1985, were the first to note EMA expression in perineurial cells. Epithelial membrane antigen is an incompletely characterized antigen that is found in a group of carbohydrate-rich, protein-poor, high- molecular-weight molecules detected on the surface of many types of epithelia. 54 After Pinkus and Kurtin's article,54 many other reports have shown EMA expression in perineuriomas, turning this marker into an important adjunct in differentiating perineurioma from its morphologic mimickers.55 Nevertheless, the use of EMA as a perineurial marker presents some drawbacks. First, the cytoplasmic processes of perineurial cells are extremely thin and widely separated, and EMA reactivity may be difficult to demonstrate without using higher antisera concentrations or longer incubation times than routinely employed in the diagnosis of epithelial neoplasms; even when these precautions are taken, sometimes EMA positivity may be focal and weak.9 The literature contains examples of ultrastructurally welldocumented EMA-negative perineuriomas.10,56 Second, EMA expression in soft tissue neoplasms is not restricted to perineuriomas; it can be detected in neoplasms with (myo)fibroblastic differentiation as well as in synovial sarcomas, in epithelioid sarcomas,26,42,57 and in other mesenchymal neoplasms. To diminish these problems, two additional protein markers have recently been reported to be helpful in confirming the diagnosis of perineurioma: claudin-1 and human erythrocyte glucose transporter-1 (GLUT-1).
Claudins are a group of 20 homologous transmembrane proteins, of which claudin-1 and claudin-2 were identified as the main integral components of tight junctions in epithelial and endothelial cells.58,59 Recent studies have shown expression of different claudin proteins in solid tumors, such as ovarian carcinoma60 and synovial sarcomas. 61 Folpe et al62 evaluated the expression of different tight junction-associated proteins in nonneoplastic soft tissues, and realized that claudin-1 antibody consistently detected perineurial cells of normal nerves but not other mesenchymal tissues. The explanation for this finding resides in the fact that normal and neoplastic perineurial cells contain tight junctions.63 Such finding lead Folpe et al62 to evaluate the expression of claudin-1 in perineuriomas; they found that up to 92% of their cases were positive for claudin-1, and that its membrane pattern of expression was stronger and more diffuse in a given perineurioma case than was EMA expression. Interestingly, other neoplasms with fibroblastic/myofibroblastic differentiation evaluated by these authors (DFSP, LGFS, desmoplastic fibroblastoma, and fibromatosis) did not express this antigen. Claudin-1 was detected focally in presumably perineurial cells in the periphery of neurofibromas as well as in the capsule and perivascular cells of schwannomas. Hornick and Fletcher14 have reported a lower sensitivity (about 30%) for the expression of claudin-1 in ESTP. The reasons for these heterogeneous results are probably related to the different immunohistochemical protocols used in these studies: Folpe et al62 used heat-induced epitope retrieval while Hornick and Fletcher14 did not; the latter used EnVision+ detection system (Dako, Carpinteria, Calif) while the former used a standard avidin-biotin technique.
GLUT-1 is one of several facilitative glucose transporter proteins.64 It is expressed by many normal cells, such as lymphocytes, erythrocytes, renal tubules cells, and perineurial cells, and it is also expressed by different types of carcinomas65 and epithelioid sarcoma.57 Hirose et al66 studied the pattern of expression of GLUT-1 and other immunohistochemical markers in peripheral nerve sheath tumors and found out that while GLUT-1 was strongly expressed in most perineuriomas of their series, this protein was expressed only in the capsule of schwannomas and by occasional cells in neurofibromas. The cells in neurofibromas and schwannomas that react with claudin-1, GLUT-1, and EMA are, in all probability, residual perineurial cells. These cells can proliferate on a reactive basis under certain circumstances, such as in traumatized nerves, as well as in neurofibromas and schwannomas. In the latter instances, this may not necessarily indicate a combined tumor, but rather a reactive proliferation of residual normal perineurial cells secondary to the tumor presence. Thus, although claudin-1 and GLUT-1 are not absolutely specific for perineurial differentiation, adding these proteins to the panel for the diagnosis of perineuriomas is worthwhile, especially in cases of difficult classification.
CYTOGENETICS AND MOLECULAR GENETICS
Cytogenetic studies have shown that both intraneural and extraneural perineuriomas show chromosome 22 abnormalities, mainly monosomy or deletion of the 22q11~q13.1 bands.2 Deletions and point mutations of the NF2 gene on 22q12 are frequently found in perineuriomas, but this finding can be seen in schwannomas and several other solid tumors.49,67 Recent studies have shown that chromosome 10q rearrangements or deletions seem to be a recurrent abnormality in sclerosing perineuriomas.7 An isolated case of ESTP with loss of the chromosome 13 has also been reported.68
Conventional extraneural perineuriomas have thus far followed a benign clinical course, and surgical resection with margins free of neoplasm is typically curative, regardless of subtype. However, malignant perineurioma (also known as MPNST with perineurial differentiation or perineurial MPNST) has recently been recognized as a rare variant of MPNST.40,69 Hirose et al40 reported 7 MPNSTs with perineurial differentiation situated in the subcutis of extremities and in the trunk and face, and visceral lesions involving the mediastinum and retroperitoneum of adults. None were associated with neurofibromatosis, and only 1 was associated with a nerve. As with conventional ESTP, the tumors were composed of spindle cells showing elongated and thin bipolar cytoplasmic processes, arranged in intersecting fascicles, whorls, or storiform pat\tern, sometimes forming perivascular whorls; they were embedded in a variable amount of intercellular stroma. However, malignant histologic features were also detected. Four cases were classified as high-grade by showing tumoral necrosis, exuberant cytologic atypia, or numerous mitotic figures. Three cases were labeled as low- grade malignant (see following discussion). All cases were S100 protein negative and EMA positive and showed ultrastructural features of perineurial differentiation. Malignant perineurioma is very rare, and its diagnosis may be difficult without confirmatory ultrastructural studies41 because EMA positivity is also seen in other high-grade spindle cell sarcomas (eg, epithelioid sarcoma and monophasic synovial sarcoma), as well as in spindle cell squamous cell carcinoma. Although claudin-1 and GLUT-1 have not been widely studied in malignant perineuriomas, Hirose et al66 showed that GLUT- 1 may be helpful in confirming this diagnosis. In the first series on malignant perineurioma written by Hirose et al,40 the authors suggested that this tumor would probably be less aggressive than the conventional MPNST, but the number of cases published so far is too limited to allow definitive conclusions.
The concept of "low-grade malignant perineurioma" was first introduced by Hirose et al.40 These authors found that 3 of their malignant perineurioma cases differed from the conventional perineuriomas by showing scattered cytologic atypia, infiltrative growth pattern, and higher mitotic activity. At the same time, these lesions did not fit the histologic criteria of malignancy found in the highgrade malignant perineurioma. Since none of these cases developed distant metastasis during follow-up periods that ranged from 55 to 75 months, the authors labeled such lesions as low-grade malignant perineuriomas, but they recognized the possibility that these neoplasms could represent "atypical" or "cellular" perineuriomas. Hornick and Fletcher14 reported 14 perineuriomas with atypical features in their series, 10 of which had clinical follow- up ranging from 12 to 134 months. In this series, the low-grade atypical features included scattered pleomorphic cells, abrupt transition from typical morphology to a markedly hypercellular area with cytologic atypia, and diffuse infiltration of skeletal muscle by tumor cells; of the 10 cases with such features, only 1 recurred locally, but no case metastasized. On the basis of their findings, Hornick and Fletcher14 suggested that perineuriomas with such features probably would be better called typical perineuriomas instead of low-grade malignant perineuriomas. Nevertheless, one example of perineurioma with low-grade features that behaved in a malignant fashion (with multiple distant metastases) 10 years after the initial presentation is on record.70 Moreover, only a few examples of such kind of tumor have been described so far and, even though most of those reported cases behaved in a benign fashion, limited follow-up periods are available in most reports.71-73 If one recalls that low-grade malignant mesenchymal neoplasms may take more than 10 years to metastasize, it becomes clear that additional follow-up is needed before the true potential of these tumors is known. As a result, the term perineurioma of uncertain malignant potential could also be used for cases with atypical but not overtly malignant features.
Intraneural perineurioma is a benign neoplasm, but its treatment is controversial. Put simply, in an attempt to preserve nerve function, some authors advocate diagnostic biopsy followed by neurolysis instead of resection,2 while others prefer the resection with neural grafting or end-to-end anastomosis because, according to them, intraneural perineurioma is a progressive condition that evolves inexorably to a total loss of nerve function.74
Perineurioma is an uncommon and underrecognized benign neoplasm that exhibits histologic features that overlap with those of many other benign and malignant soft tissue tumors. The correct diagnosis relies mainly on histologic findings and immunohistochemical profile, but ultrastructural studies can be used in difficult cases. Cytogenetic and molecular genetic studies are still of limited value for the diagnosis of perineuriomas but may play a fundamental role in excluding important differential diagnostic considerations, such as DFSP and low-grade fibromyxoid sarcoma.
Note.-In this article we state that perineuriomas have never previously been associated with neurofibromatosis. However, after our article was accepted for publication, an article describing the occurrence of a soft tissue perineurioma in the clinical setting of neurofibromatosis type 2 was published. The reference for this recent article is Pitchford CW, Schwartz HS, Atkinson JB, Cates JM. Soft tissue perineurioma in a patient with neurofibromatosis type 2: a tumor not previously associated with the NF2 syndrome. Am J Surg Pathol. 2006;30:1624-1629.
The authors thank the following colleagues from Mayo Clinic: Antonio G. Nascimento, MD, for allowing the corresponding author to use his file cases in order to obtain photomicrographs from extraneural soft tissue perineuriomas and sclerosing perineuriomas; Bernd W. Scheithauer, MD, who kindly provided the illustrations of extraneural perineurioma macroscopy, perineurioma electron microscopy, and intraneural perineurioma; and Mr. Brent T. Vrieze for his computer and digital imaging support. The authors are grateful to Emilio M. Pereira, MD, from the Laboratorio Salomao e Zoppi, Sao Paulo, Brazil, for kindly providing some of the sclerosing perineurioma photomicrographs. They are in debt to Christopher D. M. Fletcher, MD, FRCPath, from the Brigham and Women's Hospital, Boston, Mass, for promptly ceding a histhologic image of reticular perineurioma; and to Mr Marcos Franchi and Mrs Celene Gandin, from the Universidade Estadual Paulista-UNESP, Botucatu, Brazil, for their skilled assistance on immunohistochemistry.
1. Lazarus SS, Trombetta LD. Ultrastructural identification of a benign perineurial cell tumor. Cancer. 1978;41:1823-1829.
2. Emory TS, Scheithauer BW, Hirose T, Wood M, Onofrio BM, Jenkins RB. Intraneural perineurioma: a clonal neoplasm associated with abnormalities of chromosome 22. Am J Clin Pathol. 1995;103:696- 704.
3. Mentzel T, Dei Tos AP, Fletcher CD. Perineurioma (storiform perineurial fibroma): clinico-pathological analysis of four cases. Histopathology. 1994;25: 261-267.
4. Shanthaveerappa TR, Bourne GH. Perineural epithelium: a new concept of its role in the integrity of the peripheral nervous system. Science. 1966;154:1464-1467.
5. Balarezo FS, Muller RC, Weiss RG, Brown T, Knibbs D, Joshi VV. Soft tissue perineuriomas in children: report of three cases and review of the literature. Pediatr Dev Pathol. 2003;6:137-141.
6. Fetsch JF, Miettinen M. Sclerosing perineurioma: a clinicopathologic study of 19 cases of a distinctive soft tissue lesion with a predilection for the fingers and palms of young adults. Am J Surg Pathol. 1997;21:1433-1442.
7. Brock JE, Perez-Atayde AR, Kozakewich HP, Richkind KE, Fletcher JA,Vargas SO. Cytogenetic aberrations in perineurioma: variation with subtype. Am J Surg Pathol. 2005;29:1164-1169.
8. Hirose T, Scheithauer BW. "Sclerosing" perineurioma: a tumor variant? Int J Surg Pathol. 1999;7:133-140.
9. Scheithauer BW, Woodruff JM, Erlandson RA. Tumors of the Peripheral Nervous System. Washington, DC: Armed Forces Institute of Pathology; 1999. Atlas of Tumor Pathology; 3rd series, fascicle 24.
10. Giannini C, Scheithauer BW, Jenkins RB, et al. Soft-tissue perineurioma: evidence for an abnormality of chromosome 22, criteria for diagnosis, and review of the literature. Am J Surg Pathol. 1997;21:164-173.
11. Graadt van Roggen JF, McMenamin ME, Belchis DA, Nielsen GP, Rosenberg AE, Fletcher CD. Reticular perineurioma: a distinctive variant of soft tissue perineurioma. Am J Surg Pathol. 2001;25:485- 493.
12. Michal M. Extraneural retiform perineuriomas: a report of four cases. Pathol Res Pract. 1999;195:759-763.
13. Robson AM, Calonje E. Cutaneous perineurioma: a poorly recognized tumour often misdiagnosed as epithelioid histiocytoma. Histopathology. 2000;37: 332-339.
14. Hornick JL, Fletcher CD. Soft tissue perineurioma: clinicopathologic analysis of 81 cases including those with atypical histologic features. Am J Surg Pathol. 2005;29:845-858.
15. Giannini C, Scheithauer BW, Steinberg J, Cosgrove TJ. Intraventricular perineurioma: case report. Neurosurgery. 1998;43:1478-1481.
16. Hornick JL, Fletcher CD. Intestinal perineuriomas: clinicopathologic definition of a new anatomic subset in a series of 10 cases. Am J Surg Pathol. 2005; 29:859-865.
17. Val-Bernal JF, Hernando M, Garijo MF, Villa P. Renal perineurioma in childhood. Gen Diagn Pathol. 1997;143:75-81.
18. Ortonne JP, Verrando P, Pautrat G, Darmon M. Lamellar cells of sensory receptors and perineural cells of nerve endings of pig skin contain cytokeratins. Virchows Arch A Pathol Anat Histopathol. 1987;410:547-552.
19. Meis JM, Ordonez NG, Bruner JM. Meningiomas: an immunohistochemical study of 50 cases. Arch Pathol Lab Med. 1986;110:934-937.
20. Zamecnik M, Michal M, Baumruk L, Mukensnabl P. Dermatofibrosarcoma protuberans with EMa+ cells: report of a case suggesting perineurial cell differentiation. Pathol Res Pract. 2002;198:767-774.
21. Sirvent N, Maire G, Pedeutour F. Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer. 2003;37:1-19.
22. Ohno T, Park P, Akai M, et al. Ultrastructural study of a perineurioma. Ultrastruct Pathol. 1988;12:495-504.
23. Gelli MC, Pasquinelli G, Martinelli G, Gardini G. Cutaneous meningioma: histochemical, immunohistochemical and ultrastructural investigation. Histopathology. 1993;23:576-578.
24. Peltonen J, Jaakkola S, Virtanen I, Pell\iniemi L. Perineurial cells in culture: an immunocytochemical and electron microscopic study. Lab Invest. 1987;57: 480-488.
25. Mertens F, Fletcher CD, Antonescu CR, et al. Clinicopathologic and molecular genetic characterization of low- grade fibromyxoid sarcoma, and cloning of a novel FUS/CREB3L1 fusion gene. Lab Invest. 2005;85:408-415.
26. Gengler C, Guillou L. Solitary fibrous tumour and haemangiopericytoma: evolution of a concept. Histopathology. 2006;48:63-74.
27. Feany MB, Anthony DC, Fletcher CD. Nerve sheath tumours with hybrid features of neurofibroma and schwannoma: a conceptual challenge. Histopathology. 1998;32:405-410.
28. Zamecnik M, Michal M. Perineurial cell differentiation in neurofibromas: report of eight cases including a case with composite perineurioma-neurofibroma features. Pathol Res Pract. 2001;197:537- 544.
29. Michal M, Kazakov DV, Belousova I, Bisceglia M, Zamecnik M, Mukensnabl P. A benign neoplasm with histopathological features of both schwannoma and retiform perineurioma (benign schwannoma- perineurioma): a report of six cases of a distinctive soft tissue tumor with a predilection for the fingers. Virchows Arch. 2004;445:347-353.
30. Kazakov DV, Pitha J, Sima R, et al. Hybrid peripheral nerve sheath tumors: schwannoma-perineurioma and neurofibroma- perineurioma: a report of three cases in extradigital locations. Ann Diagn Pathol. 2005;9:16-23.
31. Bundock EA, Fletcher CDM. Nerve sheath tumors with hybrid features of perineurioma and schwannoma [abstract]. Mod Pathol. 2004;17:12A.
32. Val-Bernal JF, Garijo MF, Val D. Response to "Intratumoral fat in neurofibroma." Am J Dermatopathol. 2003;25:174-175.
33. Miettinen M. Nerve sheath tumors. In: Miettinen M, ed. Diagnostic Soft Tissue Pathology. Philadelphia, Pa: Churchill Livingstone; 2003:343-378.
34. Pulitzer DR, Martin PC, Reed RJ. Fibroma of tendon sheath: a clinicopathologic study of 32 cases. Am J Surg Pathol. 1989;13:472- 479.
35. Ushigome S, Takakuwa T, Hyuga M, Tadokoro M, Shinagawa T. Perineurial cell tumor and the significance of the perineurial cells in neurofibroma. Acta Pathol Jpn. 1986;36:973-987.
36. Mentzel T, Kutzner H. Reticular and plexiform perineurioma: clinicopathological and immunohistochemical analysis of two cases and review of perineurial neoplasms of skin and soft tissues. Virchows Arch. 2005;447:677-682.
37. Shelekhova K, Kazakov DV, Michal M. Infiltrating retiform perineurioma: a case report. Ann Diagn Pathol. 2005;9:293-294.
38. de La Jarte-Thirouard AS, Jacquier I, de Saint-Maur PP. Intraneural reticular perineurioma of the neck. Ann Diagn Pathol. 2003;7:120-123.
39. Kilpatrick SE, Hitchcock MG, Kraus MD, Calonje E, Fletcher CD. Mixed tumors and myoepitheliomas of soft tissue: a clinicopathologic study of 19 cases with a unifying concept. Am J Surg Pathol. 1997;21:13-22.
40. Hirose T, Scheithauer BW, Sano T. Perineurial malignant peripheral nerve sheath tumor (MPNST): a clinicopathologic, immunohistochemical, and ultrastructural study of seven cases. Am J Surg Pathol. 1998;22:1368-1378.
41. Graadt van Roggen JF, Hogendoorn PC, Fletcher CD. Myxoid tumours of soft tissue. Histopathology. 1999;35:291-312.
42. Lasota J, Jasinski M, biec-Rychter M, Szadowska A, Limon J, Miettinen M. Detection of the SYT-SSX fusion transcripts in formaldehyde-fixed, paraffin-embedded tissue: a reverse transcription polymerase chain reaction amplification assay useful in the diagnosis of synovial sarcoma. Mod Pathol. 1998;11:626-633.
43. Huguet P, de la TJ, Pallares J, et al. Intraosseous intraneural perineurioma: report of a case with morphological, immunohistochemical and FISH study. Med Oral. 2004;9:64-68.
44. Damm DD, White DK, Merrell JD. Intraneural perineurioma not restricted to major nerves. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;96: 192-196.
45. Chang Y, Horoupian DS, Jordan J, Steinberg G. Localized hypertrophic mononeuropathy of the trigeminal nerve. Arch Pathol Lab Med. 1993;117:170-176.
46. Neary D, Ochoa J. Localized hypertrophic neuropathy, intraneural tumour, or chronic nerve entrapment? [letter]. Lancet. 1975;1:632-633.
47. Mitsumoto H, Wilbourn AJ, Goren H. Perineurioma as the cause of localized hypertrophic neuropathy. Muscle Nerve. 1980;3:403-412.
48. Bilbao JM, Khoury NJ, Hudson AR, Briggs SJ. Perineurioma (localized hypertrophic neuropathy). Arch Pathol Lab Med. 1984;108:557-560.
49. Lasota J, Fetsch JF, Wozniak A, Wasag B, Sciot R, Miettinen M. The neurofibromatosis type 2 gene is mutated in perineurial cell tumors: a molecular genetic study of eight cases. Am J Pathol. 2001;158:1223-1229.
50. Diaz-Flores L, Alvarez-Arguelles H, Madrid JF, Varela H, Gonzalez MP, Gutierrez R. Perineurial cell tumor (perineurioma) with granular cells. J Cutan Pathol. 1997;24:575-579.
51. Rank JP, Rostad SW. Perineurioma with ossification: a case report with immunohistochemical and ultrastructural studies. Arch Pathol Lab Med. 1998; 122:366-370.
52. Zamecnik M. Perineurioma with adipocytes (lipomatous perineurioma). Am J Dermatopathol. 2003;25:171-173.
53. Burgues O, Monteagudo C, Noguera R, Revert A, Molina I, Llombart-Bosch A. Cutaneous sclerosing Pacinian-like perineurioma. Histopathology. 2001;39: 498-502.
54. Pinkus GS, Kurtin PJ. Epithelial membrane antigen-a diagnostic discriminant in surgical pathology: immunohistochemical profile in epithelial, mesenchymal, and hematopoietic neoplasms using paraffin sections and monoclonal antibodies. Hum Pathol. 1985;16:929-940.
55. Scheithauer BW, Giannini C, Woodruff JM. Perineurioma. In: Kleihues P, Cavenee WK, eds. Pathology and Genetics of Tumours of the Nervous System. Lyon, France: IARC Press; 2000:169-171. World Health Organization Classification of Tumours.
56. Kahn DG, Duckett T, Bhuta SM. Perineurioma of the kidney: report of a case with histologic, immunohistochemical, and ultrastructural studies. Arch Pathol Lab Med. 1993;117:654-657.
57. Smith ME, Awasthi R, O'Shaughnessy S, Fisher C. Evaluation of perineurial differentiation in epithelioid sarcoma. Histopathology. 2005;47:575-581.
58. Furuse M, Fujita K, Hiiragi T, Fujimoto K, Tsukita S. Claudin- 1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol. 1998;141:1539-1550.
59. Gonzalez-Mariscal L, Betanzos A, Nava P, Jaramillo BE. Tight junction proteins. Prog Biophys Mol Biol. 2003;81:1-44.
60. Rangel LB, Agarwal R, D'Souza T, et al. Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res. 2003;9:2567-2575.
61. Billings SD, Walsh SV, Fisher C, Nusrat A, Weiss SW, Folpe AL. Aberrant expression of tight junction-related proteins ZO-1, claudin-1 and occludin in synovial sarcoma: an immunohistochemical study with ultrastructural correlation. Mod Pathol. 2004;17:141- 149.
62. Folpe AL, Billings SD, McKenney JK, Walsh SV, Nusrat A, Weiss SW. Expression of claudin-1, a recently described tight junction- associated protein, distinguishes soft tissue perineurioma from potential mimics. Am J Surg Pathol. 2002; 26:1620-1626.
63. Erlandson RA. The enigmatic perineurial cell and its participation in tumors and in tumorlike entities. Ultrastruct Pathol. 1991;15:335-351.
64. Mueckler M. Facilitative glucose transporters. Eur J Biochem. 1994;219: 713-725.
65. Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J. Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res. 1996;56:1164-1167.
66. Hirose T, Tani T, Shimada T, Ishizawa K, Shimada S, Sano T. Immunohistochemical demonstration of EMA/Glut1-positive perineurial cells and CD34-positive fibroblastic cells in peripheral nerve sheath tumors. Mod Pathol. 2003;16: 293-298.
67. Mertens F, Dal CP, De Wever I, et al. Cytogenetic characterization of peripheral nerve sheath tumours: a report of the CHAMP study group. J Pathol. 2000;190:31-38.
68. Mott RT, Goodman BK, Burchette JL, Cummings TJ. Loss of chromosome 13 in a case of soft tissue perineurioma. Clin Neuropathol. 2005;24:69-76.
69. Hirose T, Sumitomo M, Kudo E, et al. Malignant peripheral nerve sheath tumor (MPNST) showing perineurial cell differentiation. Am J Surg Pathol. 1989; 13:613-620.
70. Karaki S, Mochida J, Lee YH, Nishimura K, Tsutsumi Y. Low- grade malignant perineurioma of the paravertebral column, transforming into a high-grade malignancy. Pathol Int. 1999;49:820- 825.
71. Rosenberg AS, Langee CL, Stevens GL, Morgan MB. Malignant peripheral nerve sheath tumor with perineurial differentiation: "malignant perineurioma." J Cutan Pathol. 2002;29:362-367.
72. Suster D, Plaza JA, Shen R. Low-grade malignant perineurioma (perineurial sarcoma) of soft tissue: a potential diagnostic pitfall on fine needle aspiration. Ann Diagn Pathol. 2005;9:197-201.
73. Zamecnik M, Koys F, Gomolcak P. Atypical cellular perineurioma. Histopathology. 2002;40:296-299.
74. Gruen JP, Mitchell W, Kline DG. Resection and graft repair for localized hypertrophic neuropathy. Neurosurgery. 1998;43:78-83.
Ricardo S. Macarenco, MD; Fred Ellinger, MD, PhD; Andre M. Oliveira, MD
Accepted for publication September 11, 2006.
From CIPAX-Medicina Diagnostica, Sao Jose dos Campos, SP, Brazil (Dr Macarenco); the Departamento de Patologia, Faculdade de Medicina de Marilia, Marilia, SP, Brazil (Dr Ellinger); and the Division of Anatomic Pathology, Mayo Clinic, Rochester, Minn (Dr Oliveira). Dr Macarenco is currently a visiting pathologist at the Division of Anatomic Pathology, Mayo Clinic, Rochester, Minn.
The authors have no relevant financial interest in the products or companies described in this article.
Reprints: Ricardo Silvestre Macarenco, MD, Rua Itatiba, 80 Jd Apolo, Sao Jose dos Campos, Sao Paulo, Brazil (e-mail: rsmacarenco@ yahoo.com.br).
Copyright College of American Pathologists Apr 2007
(c) 2007 Archives of Pathology & Laboratory Medicine. Provided by ProQuest Information and Learning. All rights Reserved.